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Cathepsin B, a lysosomal cysteine protease, is thought to be involved in the pathogenesis
of Fasciola gigantica infection, but its exact role remains unclear. In the present
study, a recombinant F. gigantica cathepsin B (rFgCatB) protein was expressed in the
methylotrophic yeast Pichia pastoris. Western blot analysis confirmed the reactivity of
the purified rFgCatB protein to serum from F. gigantica-infected goats. The effects of
serial concentrations (10, 20, 40, 80, and 160µg/ml) of rFgCatB on various functions
of goat peripheral blood mononuclear cells (PBMCs) were examined. We demonstrated
that rFgCatB protein can specifically bind to the surface of PBMCs. In addition, rFgCatB
increased the expression of cytokines (IL-2, IL-4, IL-10, IL-17, TGF-β, and IFN-γ), and
increased nitric oxide production and cell apoptosis, but reduced cell viability. These data
show that rFgCatB can influence cellular and immunological functions of goat PBMCs.
Further characterization of the posttranslational modification and assessment of rFgCatB
in immunogenicity studies is warranted.
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INTRODUCTION
Fasciolosis, caused by the liver flukes Fasciola gigantica (F. gigantica) and Fasciola hepatica
(F. hepatica), is an important parasitic disease with a worldwide distribution (1). These liver flukes
can infect a wide range of mammalian species, including livestock, wild animals, and humans.
F. gigantica is responsible for significant economic losses in the buffalo-producing countries due
to its chronic morbidity and adverse effects on the animal health, fecundity, and productivity (2).
Adding to the challenge is the emerging evidence of F. gigantica resistance against albendazole and
rafoxanide (3), and the lack of a commercial vaccine. Better understanding of the mechanisms and
factors that shape the immuno-pathogenesis of fasciolosis may ultimately facilitate the design of
new immunotherapeutic strategies for efficient treatment of fasciolosis.
Fasciola spp. employ multiple strategies to evade the host immune response using various
molecules in their excretory/secretory (E/S) products (4–7), such as cathepsin B and L proteases
(8–10). At least six types of cathepsin B have been detected in the immature and invasive stages
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of Fasciola, and have been shown to play roles in the pathogenesis
of fasciolosis (9, 11, 12). Due to their immune-modulatory
functions, cysteine proteases such as cathepsin B have attracted
significant attention as potential immuno-therapeutic targets to
control liver fluke infection (9).
In F. hepatica, cathepsins interact with host immune cells
and skew the immune response toward a non-protective Th2-
mediated/regulatory response (13). In F. gigantica, cathepsin
B2 and B3 digest host substrates, such as immunoglobulin,
fibronectin, and collagen (14–16). Also, cathepsin B5, expressed
in immature and adult stages of F. gigantica, can digest
host proteins (17). The recombinant proteins (rFgCatB2 and
rFgCatB3) can elicit a mixed Th1/Th2 immune response with
the predominance of Th2 cytokines (16). Despite significant
efforts, information about the modulatory effects of F. gigantica
cathepsin B on the host innate immune cells is still limited.
In the present study, the gene encoding F. gigantica
cathepsin B was cloned and expressed in Pichia pastoris. We
characterized the modulatory effects of the purified recombinant
F. gigantica cathepsin B protein (rFgCatB) on various functions
of goat peripheral blood mononuclear cells (PBMCs), including
cytokine secretion, cell viability, nitric oxide (NO) production,
and apoptosis. We show that rFgCatB induces a mixed
Th1/Th2/Th17 immune response and significantly influences
other functions of goat PBMCs. Our findings demonstrate the
feasibility of including rFgCatB protein in a vaccination trial
against fasciolosis.
MATERIALS AND METHODS
Ethics Statement
All experimental protocols were reviewed and approved by
the Animal Administration and Ethics Committee of Lanzhou
Veterinary Research Institute, Chinese Academy of Agricultural
Sciences (Permit No. 2018-012). All animal experiments
were performed in strict compliance with the Animal
Ethics Procedures and Guidelines of the People’s Republic
of China. All efforts were made to minimize the suffering of
animals, and daily health checks were performed during the
entire experiments.
Animals and Collection of Blood Cells
Eight local crossbred goats (4- to 7-month-old) were obtained
from Laboratory Animal Center of Lanzhou Veterinary Research
Institute, Chinese Academy of Agriculture Science. All goats were
kept in-door and dewormed with albendazole and ivermectin
tablets (Xining Fengyuan Agricultural and Animal Sci-Tech
Company, Xining, China) to eliminate any potential existing
helminth infection. Before and 2 weeks after treatment, fecal
samples from each goat were microscopically examined for
helminth eggs. This analysis showed that all goats used in the
study are free from any prior or current helminth infection.
For the production of antisera, four female New Zealand
rabbits (3-month-old) were purchased from Laboratory Animal
Center of Lanzhou Veterinary Research Institute, Chinese
Academy of Agriculture Science and were housed under specific-
pathogen-free conditions, with access to food and water ad
libitum. Peripheral venous blood samples were collected from
three healthy goats and peripheral blood mononuclear cells
(PBMCs) andmonocytes were isolated and cultured as previously
described (7).
Parasite Preparation
Adult flukes were harvested from the gall bladder of naturally
infected buffaloes at local slaughterhouses in Guangxi Zhuang
Autonomous Region, PR China. The harvested flukes were
washed with phosphate buffered saline (PBS, pH7.4) and
immediately used for RNA isolation or stored at −80◦C with
RNA stabilizer for future use. The flukes were identified
as F. gigantica based on amplification and sequencing of
the internal transcribed spacer 2 (ITS-2) of the ribosomal
DNA (18). Sequence alignment showed no difference between
the ITS-2 sequence obtained in our study and the ITS-
2 sequence obtained previously from F. gigantica samples
collected from buffaloes in Guangxi province (GenBank
accession No. AJ557569).
Cloning and Characterization of
FgCatB Gene
Due to the lack of genomics data on F. gigantica, we
have searched F. hepatica E/S product’s dataset produced
by liquid chromatography-tandem mass spectrometry (LC-
MS/MS), F. hepatica cDNA library available from previous
proteomic studies, and the BLASTx search protein database
(https://blast.ncbi.nlm.nih.gov/Blast.cgi), in order to identify
homologous cathepsin B protein sequences. This analysis
identified F. hepatica cathepsin B protein isoform (FhCatB)
sequence (GenBank accession No. Z22768.1), which was used
to design primers to amplify F. gigantica cathepsin B (FgCatB)
gene sequence. Total F. gigantica RNA was isolated from 30mg
of adult F. gigantica flukes using Trizol reagent (Invitrogen,
San Diego, USA). The first-strand cDNA was synthesized
by reverse transcription polymerase chain reaction (RT-PCR)
using RevertAid First Strand cDNA Synthesis Kit (Thermo
Scientific, (EU) Lithuania). The cDNA was used as a template
to amplify FgCatB gene using two oligonucleotide primers: 5′-
CCG GAA TTC CAT ATG AGC TTA CTG ATC TCC AGC-
3′ (forward) and 5′- ATT TGC GGC CGC CTC GAG TTG
GGGTAATTTTGGC-3′ (reverse). The oligonucleotide primers
were synthesized with the EcoRI (forward) or Not I (reverse)
restriction site underlined. The resulting amplified FgCatB gene
product was digested with EcoR I and Not I, and cloned into
pMD19-T (Takara, Dalian, Liaoning, China). The recombinant
plasmid was transformed into Trans5α chemically competent
cells (TransGen Biotech, Beijing, China). Several positive clones
were selected and sequenced by GenScript (Nanjing, Jiangsu,
China) to confirm the correct insertion/orientation of FgCatB
gene in the vector. The signal peptide, transmembrane helices
(TMHs) and N-glycosylation sites of the FgCatB sequence
were predicted using SignalP 5.0 Server (http://www.cbs.dtu.dk/
services/SignalP/), TMHMM Server v. 2.0 (http://www.cbs.dtu.
dk/services/TMHMM/), and NetNGlyc 1.0 Server (http://www.
cbs.dtu.dk/services/NetNGlyc/), respectively.
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Expression of rFgCatB Protein
A single positive clone containing the FgCatB gene was
selected and the FgCatB gene fragment was sub-cloned into
pPIC9K vector. A carboxyl-terminal His6 tag and appropriate
restriction sites were included in the expression plasmid to enable
purification. The plasmid designated as pPIC9K-FgCatB was
linearized with Sal I and electroporated into the methylotrophic
yeast P. pastorisGS115 strain using a GenePulser X cell TM (Bio-
Rad, Hercules, California, USA). Positive recombinant P. pastoris
clones containing the insert were selected for expression by
inoculating into 15ml of buffered complex medium containing
glycerol (BMGY). The inoculated BMGY medium (1% [wt/vol]
yeast extract, 2% [wt/vol] peptone, 1% [wt/vol] yeast nitrogen
base, 1% [wt/vol] glycerol, 0.00004% [wt/vol] biotin, and 0.1M
potassium phosphate [pH 6.0]) in 100ml conical flasks was
incubated at 28◦C with vigorous shaking for 24 h. The cells were
harvested by centrifugation (250 × g for 10min), resuspended
in 20ml of buffered complex medium containing methanol
(BMMY; BMGY medium with 1% methanol substituted for
glycerol). The culture was allowed to continue growing for 4
days. During FgCatB gene expression induction period, methanol
was added every 24 h to maintain a final concentration of 1%
(v/v). The cells were pelleted by centrifugation (2,500 × g at
4◦C for 10min) and the culture supernatant was harvested for
protein extraction.
Purification of Recombinant F. gigantica
Cathepsin B (rFgCatB) Protein
The yeast culture supernatant containing rFgCatB protein was
concentrated by centrifugation at 4,000 × g for 15min using
Amicon R© Ultra 10K centrifugal filter device. The concentrated
supernatant was purified using the His GaviTrap Kit (GE
Healthcare, Buckinghamshire, UK) at 4◦C. The rFgCatB protein
was eluted with elution buffer (20mM PBS, 0.5M NaCl, 500mM
imidazole, PH 7.4) and dialyzed against 1×PBS to remove
imidazole. The concentration of the protein was determined
by the Bradford method, using bovine serum albumin (BSA)
as the standard. Purified proteins were stored at −80◦C until
further analysis.
Preparation of Antibodies
Four, 4- to 7-month-old, goats were challenged orally with 250
viable encysted metacercariae of F. gigantica. After 3 months, the
goat sera containing anti-F. gigantica antibodies were collected.
Serum was collected from one healthy naïve goat (negative
control) and stored frozen at −80◦C. Specific antibodies against
rFgCatB protein were produced by immunizing three New
Zealand rabbits with rFgCatB. For primary immunization, 200
µg of the purified rFgCatB protein mixed with complete Freund’s
adjuvant (1:1) were injected subcutaneously into multiple sites at
the back of the rabbits, followed by four booster doses with 100
µg of the recombinant protein in incomplete Freund’s adjuvant
at 2-week intervals. One week after the last injection, antisera
against rFgCatB was collected. In the meantime, serum was
collected from one healthy rabbit (negative control) and stored
frozen at−80◦C.
SDS-PAGE and Western Blotting
The isolated protein (20 µg) was separated on 12% sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE)
gels and stained with Coomassie Blue. The protein migrated on
gels as a “blurred” smear without showing the expected band
size, indicating that rFgCatB is a glycoslyated protein. Therefore,
rFgCatB was deglycosylated under denaturing conditions using
Protein Deglycosylation Mix II (New England Biolab R© Inc.,
USA), as per the manufacturer’s instructions. The deglycosylated
rFgCatB protein was resolved on 12% SDS-PAGE gels, followed
by Coomassie Blue staining. Also, the deglycosylated rFgCatB
was transferred onto Hybond-C extra nitrocellulose membrane
(Amersham, London, UK). The membrane was blocked using
5% skim milk in Tris-buffered saline containing 0.1% Tween-20
(TBST) for 2 h at ambient temperature, followed by incubation
with primary antibodies (antiserum from goats experimentally
infected with F. gigantica) for 12 h at 4◦C (1:100 in TBST). After
being washed three times (5min each) with TBST, the membrane
was incubated with HRP-conjugated rabbit anti-goat IgG (Sigma,
St. Louis, MO, USA) for 1 h at 37◦C (1:2500 in TBST). Finally,
freshly prepared 3,3
′
-diaminobenzidine (DAB, Sigma) was used
as a chromogenic substrate to visualize the immunoreaction.
Measurement of rFgCatB Activity
The enzyme activity of rFgCatB was measured using Cathepsin
B Activity Assay Kit (Abcam, ab65300) according to the
manufacturer’s instructions. Briefly, 50 µg of rFgCatB protein
was adjusted to 50 µL per well with cell lysis buffer for
experimental samples in a 96-well plate. Fifty microliters of
blank cell lysis buffer were used for measuring background.
Next, 50 µL CB Reaction Buffer followed by 2 µL of
cathepsin B substrate Ac-RR-AFC (amino-4-trifluoromethyl
coumarin) were added to each well. The plates were incubated
at 37◦C for 2 h protected from light, and fluorescence
from the cathepsin B-cleaved substrate was measured at
excitation/emission (Ex/Em) = 400/505 nm using a fluorescent
microplate reader (Thermo scientific, Varioskan LUXMultimode
Microplate Reader). The relative enzyme activity of rFgCatB was
represented as the fold increase in the fluorescence intensity
compared with the cathepsin B inhibitor-treated control.
Immunofluorescence Detection of rFgCatB
Protein Binding to Goat PBMCs
Goat PBMCs were incubated with 10µg/ml of rFgCatB in a
humidified atmosphere of 5% CO2 at 37
◦C for 1 h. The rFgCatB-
treated cells were fixed with 4% paraformaldehyde at ambient
temperature for 15min, washed three times in PBS (5min each),
and subsequently treated with blocking solution (4% BSA in
PBS) for 1 h to minimize background staining. rFgCatB-treated
or non-treated control PBMCs were incubated with rabbit anti-
rFgCatB antibody (dilution, 1:100) for 12 h at 4◦C and washed
three times in PBS (5min each). Cells were stained with Cy3
conjugated goat anti-rabbit IgG secondary antibody (dilution,
1:500) (Beyotime, Haimen, Jiangsu, China) for 1 h at 37◦C.
Hoechst 33342 (Invitrogen, Eugene, Oregon, USA) was used to
stain the nucleus. Localization of rFgCatB was visualized using a
Zeiss laser scanning confocal microscope (LSM710, Zeiss, Jena,
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Germany) at 100 × magnification and images were analyzed
using Zen 2012 imaging software.
Cytokine Analysis
The concentrations of cytokines were evaluated in the
supernatant of 5× 104 PBMCs seeded into 24-well tissue culture
plates in 1ml RPMI 1640medium/well. Serial concentrations (10,
20, 40, 80, and 160µg/ml) of rFgCatB protein or equal volume
of PBS (control) were added to the wells. The culture plates
were incubated at 37◦C with 5% CO2 for 72 h. The supernatants
were collected and the concentrations of interleukin-2 (IL-2),
IL-4, IL-10, IL-17, interferon gamma (IFN-γ), and transforming
growth factor-beta (TGF-β) were determined using goat enzyme
linked immunosorbent assay (ELISA) kits (Mlbio, Shanghai,
China) as per the manufacturer’s instructions.
The Effect of rFgCatB Protein on
Cell Viability
The effect of rFgCatB protein on the viability of PBMCs was
examined by a CCK-8 assay (Beyotime, Haimen, Jiangsu, China).
This assay is based on the measurement of the reduction
of a water-soluble tetrazolium salt WST-8 by dehydrogenases
in viable cells. Briefly, PBMCs (104 cells/100 µl RPMI 1640
medium/well) seeded into 96-well tissue culture plates were
incubated with serial concentrations (10, 20, 40, 80, or
160µg/ml) of rFgCatB protein or equal volume of PBS (control)
at 37◦C in a humidified atmosphere with 5% CO2. Following
48 h incubation, 10 µl of CCK-8 reagent were added per well
and the culture plates were further incubated under the same
conditions for 4 h in protected from light. The optical density at
450 nm (OD450) was measured using a microplate reader (Bio-
Rad, Hercules, California, USA). TheOD450 of control wells (cells
incubated with PBS) was set as 100% and the cell viability index
was calculated using the formula: OD450 rFgCatB /OD450 control.
Determination of Nitric Oxide (NO)
PBMCs were seeded into a 24-well tissue culture plate at 5 ×
104 cells/well in 1ml RPMI 1640 medium. Cells were incubated
with various concentrations (10, 20, 40, or 80µg/ml) of rFgCatB
protein or equal volume of PBS (control) at 37◦C with 5%
CO2 for 24 h. The NO level in PBMC culture supernatant was
determined by measuring the concentrations of nitrite using
the Total Nitric Oxide Assay Kit (Beyotime, Haimen, Jiangsu,
China). A microplate reader (Bio-Rad, Hercules, California,
USA) was used to measure the absorbance values at 540 nm
(OD540). NO levels were calculated using a standard curve
generated by 0 to 80 µM/L sodium nitrites.
Evaluation of the Apoptotic Effect of
rFgCatB Protein
Flow cytometry analysis (BD Biosciences, San Jose, California,
USA) was carried out to evaluate the apoptosis in PBMCs using
the Annexin V-FITC kit (Beyotime, Haimen, Jiangsu, China).
PBMCs seeded into a 24-well tissue culture plate at 5 × 104
cells/well in 1ml RPMI 1640 medium were incubated with the
above mentioned concentrations of rFgCatB protein or equal
volume of PBS (control) at 37◦Cwith 5%CO2 for 24 h. Then, cells
were washed twice with PBS, re-suspended in binding buffer, and
stained with Annexin V and Propidium Iodide (PI) according to
the manufacturer’s instructions. The results were analyzed using
FlowJo 10.
Statistical Analysis
The statistical analyses were performed by one-way ANOVA,
followed by a Dunnett’s test or t-test using GraphPad Premier 6.0
software package (GraphPad Prism, San Diego, California, USA).
Significant differences between rFgCatB-treated and control
groups are indicated in the figures by asterisks (∗, P < 0.05;
∗∗, P < 0.01; ∗∗∗, P < 0.001 or ∗∗∗∗, P < 0.0001). Data were
presented as means ± standard deviation (SD). All experiments
were repeated at least three separate times.
RESULTS
Identification, Cloning, and Expression of
rFgCatB Protein
We performed multiple searches to identify homologous of
F. gigantica cathepsin B sequence in the genome of F. hepatica.
This analysis identified F. hepatica cathepsin B-like protease
(GenBank accession no. Z22768.1) sequence, which was used
to design 5
′
and 3
′
primers to amplify the FgCatB gene.
The cDNA fragment of FgCatB was successfully cloned into
the pMD19-T cloning vector and the positive pMD19-T-
FgCatB clones were subjected to nucleic acid sequencing. The
obtained FgCatB sequence has been submitted to GenBank
under accession number MN038412. The amino acid sequence
similarity search showed that cathepsin B endopeptidase of
F. hepatica (THD22097.1) has the highest similarity (100%
homology) to FgCatB. The ORF contained 1,038 base-pair
(bp) and encoded 345 amino acids. The deduced amino acid
sequence predicts the existence of a signal peptide, two N-linked
glycosylation sites and four protein kinase C phosphorylation
sites, however, no TMH was detected.
SDS-PAGE and Western Blotting Analysis
To verify the presence of FgCatB protein in F. gigantica-
derived material, FgCatB gene fragment was cloned into the
pPIC9K vector and the positive clones, designated as pPIC9K-
FgCatB, were transformed into P. pastoris. The recombinant
protein (rFgCatB) was successfully isolated from the culture
supernatant of P. pastoris. The expected molecular mass of
rFgCatB is 38.2 kDa, however after 72 h of induction with
1% methanol the purified protein exhibited a heterogeneous
molecular mass ranging from ∼36–70 kDa on SDS-PAGE.
Two bands of approximately 38 and 36 kDa appeared after
deglycosylation using endoglycosidase H (Endo H) treatment,
which cleaves high-mannose N-linked glycans (Figure 1A).
Western blot analysis using serum from F. gigantica-infected
goats confirmed the specificity of the two bands, which were
absent when the Western blot was probed with serum from
healthy goats (Figure 1B).
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FIGURE 1 | SDS-PAGE and Western blotting analysis of the rFgCatB protein
purified from the culture supernatant of P. pastoris. (A) Proteins were resolved
on 12% acrylamide gels and stained with Coomassie brilliant blue R250. Lane
M, protein molecular weight marker; Lane P, purified rFgCatB appeared
heterogeneous and ranged in size from ∼36 to 70 kDa; Lane E, rFgCatB
treatment with endoglycosidase H (Endo H) revealed two distinct bands at
∼38 and 36 kDa. (B) The protein treatment with Endo H was run under
non-reducing conditions, and visualized by immunodetection using specific
antibodies and enhanced chemiluminescence. Lane M, protein molecular
weight marker; Lane E, was loaded with rFgCatB digested with Endo H. Serum
from F. gigantica-infected goats detected ∼ 38 and 36 kDa bands; Lane C,
was loaded with rFgCatB, which did not react with serum of healthy goats.
Enzymatic Activity of rFgCatB
The activity of cathepsin B was examined using the Fluorometric
ab65300 assay kit. Fasciola gigantica-derived rFgCatB enzymatic
activity was determined by measuring its ability to cleave the
fluorescent synthetic substrate RR-AFC to release free AFC. The
results showed that the enzyme activity of rFgCatB is several fold
higher than that of the control, confirming the functional activity
for cathepsin B (Figure 2).
Binding Affinity of rFgCatB Protein to
Goat PBMCs
Indirect immunofluorescence staining was used to determine the
binding affinity of rFgCatB protein to the surface of PBMCs.
By incubating rFgCatB-treated PBMCs with rabbit anti-rFgCatB
antibodies, the localization of the red Cy3 conjugated goat anti-
rabbit IgG secondary antibody on the cell surface was observed,
suggesting successful binding of rFgCatB to the surface of PBMCs
(Figure 3). There was no fluorescence observed in the untreated
control cells.
rFgCatB Protein Increased
Cytokine Production
To understand how rFgCatB modulates cytokine production
of PBMCs, the levels of six cytokines, IL-2, IL-4, IL-10, IL-17,
IFN-γ, and TGF-β, were determined. As shown in Figure 4,
when PBMCs were treated with serial concentrations of rFgCatB
protein, the production of all six cytokines was significantly
increased compared with control (PBS-treated) PBMCs.
Cytotoxic Effect of rFgCatB Protein
We examined whether rFgCatB protein affects the viability of
PBMCs. The CCK-8 assay showed that the viability of PBMCs
FIGURE 2 | Fasciola gigantica-derived rFgCatB enzymatic activity was
determined by examining its ability to cleave the fluorescent synthetic substrate
RR-AFC to release free AFC. The enzyme activity of rFgCatB was measured
by Cathepsin B Activity Assay Kit as described in the materials and methods
and the result showed a high activity of the rFgCatB (t-test, t = 72.68,
P < 0.0001). Asterisks indicate statistical significance between rFgCatB
sample and cathepsin B inhibitor-treated control sample (****P < 0.0001).
was remarkably decreased following treatment with rFgCatB
protein, at all tested protein concentrations (Figure 5).
Nitric Oxide (NO) Production
As shown in Figure 6, compared to the control (PBS-treated
PBMCs), NO release was slightly increased in rFgCatB-treated
PBMCs at 40µg/ml and was significantly increased in rFgCatB-
treated PBMCs at 80µg/ml, but not at 10 or 20 µg/ml.
rFgCatB Protein Induced Cell Apoptosis
To explore whether rFgCatB protein induces apoptosis in
goat PBMCs, Annexin V-FITC apoptosis assay was used. The
rFgCatB protein significantly induced apoptosis in PBMCs
at all tested concentrations compared to PBS-treated, control
PBMCs (Figure 7). The apoptosis was induced in a dose-
dependent manner with the percentage of apoptotic cells
treated with rFgCatB at 10, 20, 40, and 80µg/ml were 28.88
± 2.631%, 30.95 ± 3.128%, 33.50 ± 2.152%, and 46.17 ±
5.955%, respectively.
DISCUSSION
In this study, we cloned and expressed the gene encoding
cathepsin B of F. gigantica in the methylotrophic yeast P.
pastoris. Although the expected size of the purified rFgCatB
protein with six-histidine tag is 38.2 kDa, a significant increase
in its molecular weight was observed. Yeast expression system
has been known to introduce post-translational modifications
such as glycosylation which may affect protein folding. Also,
recombinant proteins produced in P. pastoris tend to be
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FIGURE 3 | Localization of Fasciola gigantica-derived rFgCatB protein on the surface of PBMCs. Cells were treated with rFgCatB and incubated with rabbit
anti-rFgCatB primary antibody. Hoechst (blue) and Cy3-conjugated secondary antibody (red) were used to stain host cell nuclei and rFgCatB protein, respectively.
Surface localization was observed in rFgCatB-treated cells, whereas no staining was detected in untreated (control) cells. Scale bars, 10 µm.
hypermannosylated. On SDS-PAGE gels, rFgCatB appeared
as a group of bands with molecular weights between ∼36
and 70 kDa. The observed heterogeneity in the size of the
protein may be attributed to N-linked glycosylation (19).
Deglycosylation of rFgCatB using Endo H revealed ∼38 kDa
band, which corresponds to the theoretical molecular mass of
rFgCatB, and another band with molecular masse of 36 kDa,
suggesting the presence of two different glycosylated species
(i.e., diglycosylated forms) of rFgCatB, particularly, as both
reacted in Western blot. This type of finding has been also
reported for cathepsin B from the Asiatic liver fluke Opisthorchis
viverrini (20).
Our results showed that rFgCatB induced expression of
Th1 type cytokines (IL-2 and IFN-γ), Th2 type cytokines
(IL-4, IL-10, and TGF-β), and Th17 type cytokine (IL-17),
suggesting that rFgCatB can induce a mixed T helper 1
(Th1)-, Th2-, and Th17-type immune response. The high
levels of pro-inflammatory cytokines (IL-2 and IFN-γ)
and activation of monocytes have been associated with
intestinal pathology and release of NO to limit the fluke
growth (21–23). On the other hand, high expression of
Th2 anti-inflammatory cytokines can facilitate parasite
persistence, while minimizing host tissue damage (24–27).
For example, the anti-inflammatory cytokine IL-4 inhibits
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FIGURE 4 | rFgCatB protein stimulated the production of cytokines. Goat PBMCs were incubated for 72 h in the presence of PBS or serial concentrations of rFgCatB
protein. The levels of cytokines in the supernatant of cultured PBMCs were quantified by ELISA. Results showed that rFgCatB induced the expression of all examined
cytokines in a dose-dependent manner. Graphs represent means ± standard deviations of data from three independent biological replicates (IL-2 (10 µg/ml:
F (5, 36) = 46.98, P < 0.0001; 20 µg/ml: F (5, 36) = 46.98, P < 0.0001; 40 µg/ml: F (5, 36) = 46.98, P < 0.0001; 80 µg/ml: F (5, 36) = 46.98, P < 0.0001; 160 µg/ml:
F (5, 36) = 46.98, P < 0.0001), IL-4 (10 µg/ml: F (5, 36) = 43.65, P < 0.0001; 20 µg/ml: F (5, 36) = 43.65, P < 0.0001; 40 µg/ml: F (5, 36) = 43.65, P < 0.0001; 80
µg/ml: F (5, 36) = 43.65, P < 0.0001; 160 µg/ml: F (5, 36) = 43.65, P < 0.0001), IL-10 (10 µg/ml: F (5, 36) = 40.51, P = 0.0012; 20 µg/ml: F (5, 36) = 40.51,
P < 0.0001; 40 µg/ml: F (5, 36) = 40.51, P < 0.0001; 80 µg/ml: F (5, 36) = 40.51, P < 0.0001; 160 µg/ml: F (5, 36) = 40.51, P < 0.0001), IL-17 (10 µg/ml:
F (5, 36) = 77.39, P = 0.0002; 20 µg/ml: F (5, 36) = 77.39, P < 0.0001; 40 µg/ml: F (5, 36) = 77.39, P < 0.0001; 80 µg/ml: F (5, 36) = 77.39, P < 0.0001; 160 µg/ml:
F (5, 36) = 77.39, P < 0.0001), TGF-β (10 µg/ml: F (5, 36) = 137.5, P < 0.0001; 20 µg/ml: F (5, 36) = 137.5, P < 0.0001; 40 µg/ml: F (5, 36) = 137.5, P < 0.0001; 80
µg/ml: F (5, 36) = 137.5, P < 0.0001; 160 µg/ml: F (5, 36) = 137.5, P < 0.0001), and IFN-γ (10 µg/ml: F (5, 36) = 96.82, P = 0.0003; 20 µg/ml: F (5, 36) = 96.82,
P < 0.0001; 40 µg/ml: F (5, 36) = 96.82, P < 0.0001; 80 µg/ml: F (5, 36) = 96.82, P < 0.0001; 160 µg/ml: F (5, 36) = 96.82, P < 0.0001). Asterisks indicate statistical
significance between treated and untreated control PBMCs (**P < 0.01; ***P < 0.001; ****P < 0.0001 compared with control).
NO production (28) and promotes Th2 differentiation
(29), thereby facilitating the production of other anti-
inflammatory cytokines (e.g., IL-10 and TGF-β) and
inhibiting pro-inflammatory cytokines (e.g., IL-2 and IFN-
γ) (30, 31). Also, IL-10 decreases the production of IFN-γ
and IL-2 (22, 31).
TGF-β, together with other inflammatory cytokines, can
promote Th17 differentiation (32–34). Th17 cells play an
important role in host protection against various parasitic
infections by recruiting macrophages and neutrophils to infected
tissues, and through themodulation of Th1/Th2 balance (34–36).
The role of IL-17 in the inflammatory process during F. gigantica
infection has been reported (37, 38). Interestingly, TGF-β can
inhibit T cell proliferation by suppressing the production of IL-2,
and inhibiting the differentiation of Th1 and Th2 cells (39).
We have previously shown that F. gigantica proteins, rFg14-3-
34 and rFgRab10, inhibit cell proliferation, and induce apoptosis
and NO production in goat PBMCs (6, 7). The results of
the present study lend further support to these previous
findings, where rFgCatB was found to bind to the surface of
PBMCs similar to what we have demonstrated for rFg14-3-
4 and rFgRab10 proteins (6, 7), and to reduce the viability
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and increase apoptosis of PBMCs. The biological relevance
of the pro-apoptotic effect of rFgCatB on PBMCs remains
to be determined. However, induction of apoptosis, rather
than necrosis, may favor the parasite’s persistence because
apoptotic cell death does not provoke inflammatory response
(40), which can be detrimental to the parasite’s survival inside
the host.
FIGURE 5 | Effect of rFgCatB protein on PBMC viability. Goat PBMCs were
treated with PBS or with serial concentrations of rFgCatB protein and
incubated for 48 h at 37◦C at 5% CO2. Viability of cells was determined using
CCK-8 assay. Results indicate that rFgCatB protein significantly reduced the
viability of PBMCs in a dose-dependent manner. Graphs represent means ±
standard deviations of data from three independent biological replicates (10
µg/ml: ANOVA, F (5, 12) = 28.50, P = 0.0007; 20 µg/ml: ANOVA,
F (5, 12) = 28.50, P = 0.0035; 40 µg/ml: ANOVA, F (5, 12) = 28.50, P = 0.0015;
80 µg/ml: ANOVA, F (5, 12) = 28.50, P < 0.0001; 160 µg/ml: ANOVA,
F (5, 12) = 28.50, P < 0.0001). Asterisks indicate significant differences
between rFgCatB-treated and PBS-treated control cells (**P < 0.01;
***P < 0.001; ****P < 0.0001 compared with control).
The antiproliferative and pro-apoptotic effects of E/S
products of Fasciola spp. on immune cells are some of the
strategies used by these liver flukes to hamper immune
defenses, leaving the host more vulnerable to infection.
F. hepatica-derived E/S products have been shown to inhibit
the proliferation of sheep lymphoid cells, especially CD4+ T
lymphocytes (41–43), reduce the proliferation of rat spleen
mononuclear cells (44) and induce apoptosis of murine
FIGURE 6 | Effects of rFgCatB protein on the production of NO. PBMCs were
treated with PBS or with serial concentrations of rFgCatB protein and
maintained at 37◦C for 24 h. NO concentration was measured by Griess
assay. Graphs represent means ± standard deviations of data from three
independent biological replicates (10 µg/ml: ANOVA, F (4, 10) = 27.91,
P = 0.9998; 20 µg/ml: ANOVA, F (4, 10) = 27.91, P = 0.9702; 40 µg/ml:
ANOVA, F (4, 10) = 27.91, P = 0.0220; 80 µg/ml: ANOVA, F (4, 10) = 27.91,
P < 0.0001). Asterisks indicate significant differences between
rFgCatB-treated and PBS-treated control cells (*p < 0.05; ****P < 0.0001; ns,
non-significant compared with control).
FIGURE 7 | rFgCatB protein induced apoptosis in goat PBMCs. Annexin V/PI staining was used to quantify apoptotic cells by flow cytometry. (A) The FACS plot
showing apoptosis of PBMCs in response to exposure to rFgCatB protein. (B) Apoptotic cells (Annexin V+/PI-) were plotted and compared with the percentage of cell
population. Graphs represent means ± standard deviations of data from three independent biological replicates (10 µg/ml: ANOVA, F (4, 10) = 34.92, P = 0.0006; 20
µg/ml: ANOVA, F (4, 10) = 34.92, P = 0.0003; 40 µg/ml: ANOVA, F (4, 10) = 34.92, P < 0.0001; 80 µg/ml: ANOVA, F (4, 10) = 34.92, P < 0.0001). The asterisks
indicate significant differences between rFgCatB-treated and PBS-treated control goat PBMCs (***P < 0.001; ****P < 0.0001 compared with control).
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eosinophils and peritoneal macrophages (45, 46). Also,
immunosuppression of CD4+ T lymphocytes has been observed
in F. hepatica-infected goats (47). Additionally, F. hepatica
can induce apoptosis in sheep PBMCs by up-regulating
the expression of TNF-α and TNFR1/TNFR2 (48). The
induction of apoptosis in sheep eosinophils (49) and peritoneal
leucocytes (50) has been suggested to play a role in the
pathogenesis of F. hepatica by supporting the survival of the
juvenile parasites during the migratory and biliary stages
of infection.
In summary, our data show that rFgCatB interacts with serum
from goats infected with F. gigantica and accumulates at the
surface of PBMCs. The importance of our data resides in the
fact that rFgCatB represents a new mechanism for F. gigantica
to evade the host’s immune response through modulation of
the immune response and biological functions of PBMCs.
Exposure of these cells to rFgCatB caused increased production
of cytokines (IL-2, IL-4, IL-10, IL-17, TGF-β, and IFN-γ),
increased NO production, increased apoptosis, and inhibition of
cell viability. Our data provide a proof of concept that rFgCatB is
involved F. gigantica-interaction with immune cells. In the light
of these findings and given that rFgCatB and other F. gigantica-
derived proteins (e.g., rFg14-3-34 and rFgRab10) can modulate
key cellular and immunological functions of goat PBMCs, future
work should focus on identifying the appropriate synergistic
combinations of these proteins to develop a cocktail vaccine for
testing against F. gigantica infection.
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